GeoVax Labs Inc
GOVXW0.004USD
0.0000.00%
Close 12/24, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of GeoVax Labs Inc Company
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
GeoVax Labs Inc Info
Ticker SymbolGOVXW
Company nameGeoVax Labs Inc
IPO dateApr 04, 1994
CEOMr. David A. Dodd
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address1900 Lake Park Drive
CitySMYRNA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code30080
Phone16783847220
Websitehttps://www.geovax.com/
Ticker SymbolGOVXW
IPO dateApr 04, 1994
CEOMr. David A. Dodd
Company Executives of GeoVax Labs Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Mark J. Newman, Ph.D.
Dr. Mark J. Newman, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. John W. Sharkey, Ph.D.
Dr. John W. Sharkey, Ph.D.
Vice President - Business Development
Vice President - Business Development
--
--
Dr. Kelly T. Mckee, M.D.
Dr. Kelly T. Mckee, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Dean G. Kollintzas
Mr. Dean G. Kollintzas
Independent Director
Independent Director
--
--
Dr. Jayne Morgan, M.D.
Dr. Jayne Morgan, M.D.
Independent Director
Independent Director
--
--
Mr. David A. Dodd
Mr. David A. Dodd
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Mark W. Reynolds, CPA
Mr. Mark W. Reynolds, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Dr. Randal D. Chase, Ph.D.
Dr. Randal D. Chase, Ph.D.
Independent Director
Independent Director
--
--
Dr. Robert T. McNally, Ph.D.
Dr. Robert T. McNally, Ph.D.
Independent Director
Independent Director
--
--
Mr. John N. (Jack) Spencer, Jr.
Mr. John N. (Jack) Spencer, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Mark J. Newman, Ph.D.
Dr. Mark J. Newman, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. John W. Sharkey, Ph.D.
Dr. John W. Sharkey, Ph.D.
Vice President - Business Development
Vice President - Business Development
--
--
Dr. Kelly T. Mckee, M.D.
Dr. Kelly T. Mckee, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Dean G. Kollintzas
Mr. Dean G. Kollintzas
Independent Director
Independent Director
--
--
Dr. Jayne Morgan, M.D.
Dr. Jayne Morgan, M.D.
Independent Director
Independent Director
--
--
Mr. David A. Dodd
Mr. David A. Dodd
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Aug 23
Updated: Sat, Aug 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
9
199.66K
0.00%
+63.35K
2025Q2
5
135.67K
0.00%
+25.74K
2025Q1
5
135.67K
0.00%
+25.74K
2024Q4
5
109.14K
0.00%
+38.29K
2024Q3
5
70.06K
0.00%
+3.06K
2024Q2
5
66.89K
0.00%
-40.46K
2024Q1
5
107.26K
0.00%
+26.11K
2023Q4
5
81.05K
0.00%
+12.95K
2023Q3
4
68.10K
0.00%
-17.74K
2023Q2
4
68.10K
0.00%
-17.74K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Marex Group plc
10.00K
0%
+10.00K
--
Jun 30, 2025
Citadel Advisors LLC
21.41K
0%
+21.41K
--
Jun 30, 2025
Two Sigma Investments, LP
14.52K
0%
+14.52K
--
Jun 30, 2025
BofA Global Research (US)
172.00
0%
+172.00
--
Jun 30, 2025
Susquehanna International Group, LLP
99.38K
0%
+17.66K
+21.62%
Jun 30, 2025
Heights Capital Management, Inc.
53.96K
0%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
--
0%
-539.00
-100.00%
Sep 30, 2024
Clear Street LLC
222.00
0%
+222.00
--
Jun 30, 2025
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of GeoVax Labs Inc?
The top five shareholders of GeoVax Labs Inc are:
Marex Group plc holds 10.00K shares, accounting for 0.00% of the total shares.
Citadel Advisors LLC holds 21.41K shares, accounting for 0.00% of the total shares.
Two Sigma Investments, LP holds 14.52K shares, accounting for 0.00% of the total shares.
BofA Global Research (US) holds 172.00 shares, accounting for 0.00% of the total shares.
Susquehanna International Group, LLP holds 99.38K shares, accounting for 0.00% of the total shares.
Marex Group plc holds 10.00K shares, accounting for 0.00% of the total shares.
Citadel Advisors LLC holds 21.41K shares, accounting for 0.00% of the total shares.
Two Sigma Investments, LP holds 14.52K shares, accounting for 0.00% of the total shares.
BofA Global Research (US) holds 172.00 shares, accounting for 0.00% of the total shares.
Susquehanna International Group, LLP holds 99.38K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of GeoVax Labs Inc?
The top three shareholder types of GeoVax Labs Inc are:
Other
Other
How many institutions hold shares of GeoVax Labs Inc (GOVXW)?
As of 2025Q3, 9 institutions hold shares of GeoVax Labs Inc, with a combined market value of approximately 199.66K, accounting for --% of the total shares. Compared to 2025Q2, institutional shareholding has increased by --.
What is the biggest source of revenue for GeoVax Labs Inc?
In --, the -- business generated the highest revenue for GeoVax Labs Inc, amounting to -- and accounting for --% of total revenue.
